Bio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest

Simply Wall St.03-17

Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620953495?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-03-17 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620953495","market":"nz","top_or_hot":-1,"title":"Bio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest","media":"Simply Wall St.","content":"<div>\n<p>Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/biotechne-tech-valuation-check-after-earnings-beat-and-renew\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio‑Techne (TECH) Valuation Check After Earnings Beat And Renewed Institutional Interest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 01:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/biotechne-tech-valuation-check-after-earnings-beat-and-renew><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/biotechne-tech-valuation-check-after-earnings-beat-and-renew\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH.AU","symbol_name":"GLOBAL X MORNINGSTAR GLOBAL","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/biotechne-tech-valuation-check-after-earnings-beat-and-renew","article_id":"2620953495","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/biotechne-tech-valuation-check-after-earnings-beat-and-renew","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620953495","pubTimestamp":1773681497,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on the life sciences supplier.\nSee our latest analysis for Bio-Techne.\nDespite the upbeat quarter and renewed institutional interest, the 30 day share price return of a 15.15% decline and 1 year total shareholder return of an 18.27% loss show momentum has been weak, with pressure building across both...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TECH.AU":"GLOBAL X MORNINGSTAR GLOBAL","TECH":"Techne Corporation"},"translate_title":"Bio-Techne(TECH)盈利超出预期并重新引起机构兴趣后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH.AU":1.5,"TECH":1.5},"content_text":"Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on the life sciences supplier. See our latest analysis for Bio-Techne. Despite the upbeat quarter and renewed institutional interest, the 30 day share price return of a 15.15% decline and 1 year total shareholder return of an 18.27% loss show momentum has been weak, with pressure building across both shorter and longer horizons. If Bio-Techne’s recent moves have you rethinking where growth could come from in life sciences and diagnostics, it can be useful to scan related healthcare and AI names through our discovery focused 34 healthcare AI stocks With Bio-Techne trading at US$50.85, alongside an indicated 29% intrinsic discount and a 48% gap to analyst targets, recent weakness raises the key question: is this a genuine entry point or is the market already discounting future growth? AdvertisementMost Popular Narrative: 32.4% Undervalued Against a last close of $50.85, the most followed narrative anchors Bio-Techne’s fair value at $75.25, built on detailed revenue and margin forecasts discounted at 7.83%.  The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100 to 200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (for example, Leo Simple Western and Maurice) and digital platforms are driving high margin, high throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.  Read the complete narrative. Curious how a relatively modest revenue growth path, changing profit margins and a rich future earnings multiple all line up to support that $75.25 figure? The narrative lays out a tight set of assumptions about earnings power and valuation that the current share price is not reflecting. Result: Fair Value of $75.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that story can unravel quickly if biotech funding remains weak, or if geopolitical and regulatory pressures push large pharma and international customers to pull back spending. Find out about the key risks to this Bio-Techne narrative. Another View: Earnings Multiple Sends a Different Signal The fair value narrative leans on discounted future cash flows, but the current P/E of 98.1x is far above the North American Life Sciences average of 32.1x, the peer average of 20.4x, and the fair ratio of 24x. That gap suggests meaningful valuation risk if sentiment or growth expectations reset. The key question is which signal matters more for you. For a closer look at how the current pricing stacks up on earnings relative to peers and where the fair ratio sits, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TECH P/E Ratio as at Mar 2026Next Steps If this mix of optimism and concern feels familiar, do not sit on the sidelines. Instead, check the balance of 3 key rewards and 2 important warning signs Looking for more investment ideas? If Bio-Techne has sharpened your focus on quality and price, do not stop here. Use screeners to surface fresh ideas that fit your own checklist.  Target reliability by focusing on companies flagged in our 74 resilient stocks with low risk scores that may offer steadier return profiles and fewer financial surprises. Hunt for potential bargains by scanning the 49 high quality undervalued stocks and see which names currently trade below their assessed worth with solid fundamentals. Prioritize resilience by filtering for companies in the solid balance sheet and fundamentals stocks screener (42 results) that pair manageable debt levels with robust financial footing.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bio-Techne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620953495","isCrawlerRequest":true}